Experienced in Lung Metastases

Ewald Woll

St. Vinzenz Krankenhaus Betriebs GmbH
Zams, AT 
Experienced in Lung Metastases
St. Vinzenz Krankenhaus Betriebs GmbH
Zams, AT 
OverviewLocationsClinical Research

Overview

Ewald Woll practices in Zams, Austria. Mr. Woll is rated as an Experienced expert by MediFind in the treatment of Lung Metastases. His top areas of expertise are Stomach Cancer, COVID-19, Multiple Myeloma, and Severe Acute Respiratory Syndrome (SARS).

His clinical research consists of co-authoring 52 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Lung Metastases.

Gender
Male

Locations

St. Vinzenz Krankenhaus Betriebs GmbH
Zams, 6511, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Dronabinol in the Improvement of ChemOthErapy-induced and Tumor-Related Symptoms in Patients With Locally Advanced or Metastatic Pancreatic Cancer During First-line Chemotherapy (DIsCOvER)
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Dronabinol in the Improvement of ChemOthErapy-induced and Tumor-Related Symptoms in Patients With Locally Advanced or Metastatic Pancreatic Cancer During First-line Chemotherapy (DIsCOvER)
Enrollment Status: Completed
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drug: Dronabinol
Study Phase: Phase 3
Isatuximab in Combination With Lenalidomide-Dexamethasone Compared to Lenalidomide-Dexamethasone in Elderly Patients (Aged ≥70 Years) With Newly Diagnosed Myeloma: a Randomized Phase II Study (SGZ-2019-12650)
Isatuximab in Combination With Lenalidomide-Dexamethasone Compared to Lenalidomide-Dexamethasone in Elderly Patients (Aged ≥70 Years) With Newly Diagnosed Myeloma: a Randomized Phase II Study (SGZ-2019-12650)
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: Isatuximab-Irfc [Sarclisa], Lenalidomide, Dexamethasone Oral
Study Phase: Phase 2
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients- a Randomized, Placebo Controlled Phase II Trial DEFENCE (DEnosumab For the rEductioN of the Smoldering Myeloma transformatioN inCidence ratE)
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients- a Randomized, Placebo Controlled Phase II Trial DEFENCE (DEnosumab For the rEductioN of the Smoldering Myeloma transformatioN inCidence ratE)
Enrollment Status: Completed
Publish Date: February 11, 2025
Intervention Type: Drug
Study Drug: Denosumab
Study Phase: Phase 2
A Randomized Phase II, 2-armed Study in Transplant Ineligible (TI) Patients With Newly Diagnosed Multiple Myeloma (NDMM) Comparing Carfilzomib + Thalidomide + Dexamethasone (KTd) Versus Carfilzomib + Lenalidomide + Dexamethasone (KRd) Induction Therapy With Respect to Response Rates and Investigating a Carfilzomib (K) Monotherapy Maintenance Strategy
A Randomized Phase II, 2-armed Study in Transplant Ineligible (TI) Patients With Newly Diagnosed Multiple Myeloma (NDMM) Comparing Carfilzomib + Thalidomide + Dexamethasone (KTd) Versus Carfilzomib + Lenalidomide + Dexamethasone (KRd) Induction Therapy With Respect to Response Rates and Investigating a Carfilzomib (K) Monotherapy Maintenance Strategy
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Drug
Study Drugs: Carfilzomib, Thalidomide, Lenalidomide, Dexamethasone
Study Phase: Phase 2
View 3 Less Clinical Trials

52 Total Publications

Response to comments on "Health risk factors in different educational groups and their association to Barrett's esophagus".
Response to comments on "Health risk factors in different educational groups and their association to Barrett's esophagus".
Journal: Wiener klinische Wochenschrift
Published: August 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Woll's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile